African Swine Fever roadmap:
Vaccines
Roadmap for the development of a candidate vaccine for ASF
Download ASF Vaccine Roadmap1
Vaccine
Dependencies
- 2 Naturally attenuated candidates
- 2A Safety
- 2B Delivery route
- 2C Delivery platform
- 2D Efficacy in challenge model
- 3 Rationally attenuated candidates
- 3A Safety
- 3B Delivery route
- 3C Delivery platform
- 3D Efficacy in challenge model
- 4 Inactivated vaccines
- 4A Safety
- 4B Delivery route
- 4C Delivery platform
- 4D Safety
- 5, 6 DNA/RNA vaccines/Subunit vaccines
- 5, 6A Safety
- 5, 6B Delivery route
- 5, 6C Delivery platform
- 5, 6D Efficacy in challenge model
- 7 Vectored vaccines
- 7A Safety
- 7B Delivery route
- 7C Delivery platform
- 7D Efficacy in challenge model
Vaccine
Research Question
- Highly efficacious and safe
- Rapid onset of immunity
- Long lasting protection following one shot immunisation (at least 1-year)
- Cross-protection against the various ASFV virus strains
- No reversion to virulence
- Virus eradication from a herd or a population
- Oral administration for wild suids
Research Gaps and Challenges
- Even homologous protective immunity is very difficult to achieve
- Cross-protection against the various isolates (heterologous protection)
- Generation of both a CTC and VN response
- The dominant immunogens may not be protective
Solution Routes
- Establish protection levels with various candidate vaccine options, including priming with one vaccine and boosting with a different vaccine
- Establish if pig genetics influences responses
Dependencies
- Development of an attenuated vaccine that doesn’t persist or is excreted
- Development of a subunit vaccine
- Development of a vector vaccine
- Development of a DNA vaccine
State Of the Art
- Several prototypes are presented, but all are far away from a real vaccine candidate
Projects
What activities are planned or underway?
Africa's Long Depression: The Growth and Debt Crises of 1975-2000
Planned Completion date 01/03/2027
Participating Country(s):
United Kingdom
Unlocking potential: developing innovative adolescent screening visits for health promotion, prevention and treatment in low-resource settings
Planned Completion date 01/01/2028
Participating Country(s):
United Kingdom